Simmunome Inc.

Simmunome builds AI-driven computational disease models for use in clinical R&D. The venture focuses on accurately replicating biological processes to simulate clinical trial outcomes without the need for a client to step into a lab. The venture has two validated models: for Alzheimer’s disease and melanoma. Simmunome’s  target markets span big pharma, small/mid-size biotech, and academia.